BDBM577692 US11478451, Example 096::US11478451, Example 097::US11478451, Example 098

SMILES CCc1c-2c(COCCC(F)(F)Cn3c(C(O)=O)c(CCCOc4cccc5cc(F)ccc45)c4ccc(Cl)c-2c34)nn1C

InChI Key InChIKey=HRVSPZYJJJPUPB-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 577692   

LigandPNGBDBM577692(US11478451, Example 096 | US11478451, Example 097 ...)
Affinity DataIC50:  1.30nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577692(US11478451, Example 096 | US11478451, Example 097 ...)
Affinity DataIC50:  1.20E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM577692(US11478451, Example 096 | US11478451, Example 097 ...)
Affinity DataIC50:  1.20E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577692(US11478451, Example 096 | US11478451, Example 097 ...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577692(US11478451, Example 096 | US11478451, Example 097 ...)
Affinity DataIC50:  20nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM577692(US11478451, Example 096 | US11478451, Example 097 ...)
Affinity DataIC50:  1.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM577692(US11478451, Example 096 | US11478451, Example 097 ...)
Affinity DataIC50: >2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent